National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

For the treatment of adults with previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) (i.e. in the 2nd / 3rd–line treatment setting)

Rapid Review

Commenced Completed Outcome
09/01/2013 31/01/2013 Full Pharmacoeconomic Evaluation Recommended

Pharmacoeconomic Evaluation

Commenced Completed Outcome
24/05/2013  27/08/2013 Reimbursement not recommended

The NCPE do not consider Crizotinib (Xalkori®) a cost-effective treatment for adult patients with previously treated ALK positive advanced non small cell lung cancer (NSCLC).

Crizotinib summary

August 2015

The HSE has approved reimbursement following confidential price negotiations.